Islatravir Recruiting Phase 3 Trials for Prophylaxis / Human Immunodeficiency Virus Type 1 (HIV-1) Prevention

IndicationsStatusPurposePhase
RecruitingPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT04644029Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)